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Introduction
Glioblastoma (GBM) is a hypervascular malignant brain tumor with poor prognosis,
even with the best combination of treatments.1 The hypervascular nature of GBM has
made antiangiogenic treatment (AAT) a popular adjuvant to inhibit angiogenesis and
tumor growth.2–5 However, clinical results indicate transient beneficial effects of AAT
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Background: Due to the hypervascular nature of glioblastoma (GBM), antiangiogenic
treatments, such as vatalanib, have been added as an adjuvant to control angiogenesis and
tumor growth. However, evidence of progressive tumor growth and resistance to antiangiogenic
treatment has been observed. To counter the unwanted effect of vatalanib on GBM growth,
we have added a new agent known as N-hydroxy-N′-(4-butyl-2 methylphenyl)formamidine
(HET0016), which is a selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE)
synthesis. The aims of the studies were to determine 1) whether the addition of HET0016
can attenuate the unwanted effect of vatalanib on tumor growth and 2) whether the treatment
schedule would have a crucial impact on controlling GBM.
Methods: U251 human glioma cells (4×105) were implanted orthotopically. Two different
treatment schedules were investigated. Treatment starting on day 8 (8–21 days treatment) of the
tumor implantation was to mimic treatment following detection of tumor, where tumor would
have hypoxic microenvironment and well-developed neovascularization. Drug treatment starting
on the same day of tumor implantation (0–21 days treatment) was to mimic cases following
radiation therapy or surgery. There were four different treatment groups: vehicle, vatalanib
(oral treatment 50 mg/kg/d), HET0016 (intraperitoneal treatment 10 mg/kg/d), and combined
(vatalanib and HET0016). Following scheduled treatments, all animals underwent magnetic
resonance imaging on day 22, followed by euthanasia. Brain specimens were equally divided
for immunohistochemistry and protein array analysis.
Results: Our results demonstrated a trend that HET0016, alone or in combination with vatalanib,
is capable of controlling the tumor growth compared with that of vatalanib alone, indicating
attenuation of the unwanted effect of vatalanib. When both vatalanib and HET0016 were administered together on the day of the tumor implantation (0–21 days treatment), tumor volume, tumor
blood volume, permeability, extravascular and extracellular space volume, tumor cell proliferation, and cell migration were decreased compared with that of the vehicle-treated group.
Conclusion: HET0016 is capable of controlling tumor growth and migration, but these effects
are dependent on the timing of drug administration. The addition of HET0016 to vatalanib may
attenuate the unwanted effect of vatalanib.
Keywords: magnetic resonance imaging, glioblastoma, antiangiogenic treatments, HET0016,
vascular parameters, protein array

Dovepress

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 64.118.218.38 on 05-Jan-2017
For personal use only.

Shankar et al

(measured in weeks or months), followed by tumor restoration and progression.6 Presently, a number of compounds that
are intended to control the abnormal angiogenesis are being
studied.7,8 Agents, such as vatalanib (PTK787, a vascular
endothelial growth factor receptor 2 [VEGFR2] tyrosine kinase
inhibitor), cediranib, sunitinib, and so forth, which play a role
in interfering with the VEGFR signaling transduction pathways
have shown varying degrees of clinical success with relapse
or recurrence of tumors,4,9 thus demonstrating the development of tumor resistance to AAT.10 In some cases, inhibiting
angiogenesis has also shown an increase in lymphatic and
metastatic activities.11 Bevacizumab is a ligand-based monoclonal antibody against VEGF, unlike all of the other receptorbased therapies. According to the recently published studies,
bevacizumab in clinical settings showed adverse effect and did
not improve the patient’s survival.12,13 In GBMs, AAT actually
induced a phenotypic change from a single-cell infiltration to
a cluster of cells migrating along normal blood vessels.8,14–16
The invasive growth pattern may imply a qualitative change in
tumor response after AAT. To avoid further potential therapeutic failures, these mechanisms of resistance to antiangiogenic
therapy in clinical settings need to be better understood.
An important feature of AAT is the disrupted tumor
vasculature and associated marked hypoxia, which may be
one of the important reasons for AAT resistance. Following
marked hypoxia, a chain of mechanisms are triggered which,
we believe, establish some alternative pathways for angiogenesis via various tumor secreted factors, such as basic fibroblast
growth factor (bFGF), stromal cell-derived factor-1 alpha
(SDF-1α), protein–regulated upon activation, normal T-cell
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expressed and secreted (RANTES) or CCL5, VEGF, and
many other proangiogenic factors.4,16–19 Another potentially
distinct resistant mechanism may also be the recruitment of
endothelial progenitor cells (EPCs), as well as proangiogenic
monocytes from bone marrow to the tumor site.20 Hypoxia
creates a permissive condition for the recruitment of a heterogeneous population of monocytic bone marrow-derived cells,
which promotes angiogenesis and tumor growth.21,22
To create a clinically relevant treatment, it is important to control both tumor cell proliferation and neovascularization. N-Hydroxy-N′-(4-butyl-2-methylphenyl)
formamidine (HET0016), a highly selective inhibitor of
20-hydroxyeicosatetraenoic acid (20-HETE) synthesis,
has been reported to inhibit the enzymatic activity of the
CYP4A and CYP4F families.23 The significant findings of
treatment with HET0016 are the ability to inhibit several
growth factors, as well as angiogenesis in an U251-induced
cornea angiogenesis model.24 Further studies with HET0016
identified some of the agent’s hallmarks in controlling tumorigenesis via multiple pathways. The agent controlled the
growth of tumor cells, inhibited the effect of growth factors
on tumor angiogenesis and vasculogenesis, and inhibited
the angiogenic effects of EPCs.25,26 A possible mechanism
of action of HET0016 in relation to growth factor pathways
is shown in Figure 1. There has not been any report showing
the effectiveness of HET0016 in controlling GBM resistance
to AAT, especially vatalanib. Therefore, we hypothesize that
HET0016 has the potential to control alternative angiogenic
pathways induced by vatalanib in GBM and control the
resistant of GBM to vatalanib treatment.
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Figure 1 Possible mode of action of HET0016 in relation to growth factor pathways.
Notes: (A) Treatment with vatalanib causes decrease in expression of VEGFR2 but increases the expression of HIF-1a and VEGF, which will cause increased neovascularization
and tumor growth. (B) When HET0016 alone is used, VEGF expression is decreased through different signaling pathways, which will cause decreased neovascularization and tumor
growth. (C) When HET0016 and vatalanib are used together some of the effects of vatalanib (increase VEGF, increased neovascularization and tumor growth) can be attenuated.
Abbreviations: HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; VEGFR, vascular endothelial growth factor receptor; 20-HETE, 20-hydroxyeicosatetraenoic
acid; HIF-1α, hypoxia-inducible factor-1α; EGFR, epidermal growth factor receptor; ERK1/2, extracellular signal-regulated protein kinases 1 and 2.
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Unlike normal cerebral vasculature, hypervascular
regions of the tumor are typically permeable to contrast
agents (CAs) and thus can be detected by magnetic resonance
imaging (MRI) or computed tomography modalities. These
studies allow for the analysis of tumor size, perfusion, tumor
blood volume, permeability, and extravascular and extracellular space volume fraction. The parameters provided by
MRI help identify changes in tumor vascular physiology
after AAT. In particular, investigators have utilized dynamic
contrast-enhanced (DCE)-MRI to generate maps of vascular
permeability (forward volumetric transfer constant, Ktrans),
tumor plasma volume (vp), backward transfer constant (Kep),
and interstitial space volume fraction (ve) in GBM patients.27
These parameters may allow for a better understanding
of the physiological characteristics of the regional tumor
environment and vascularity.
The purposes of the study were to determine whether the
timing of treatment using either HET0016 and vatalanib alone
or in combination would have a crucial impact on controlling
the growth of GBM, whether addition of HET0016 would
prevent the drug resistance of GBM to vatalanib, and whether
the parametric analysis of MRI could detect significant
changes in the tumors following different treatments.

Materials and methods
Ethical statement
All animal experiments were approved and performed based
on the National Institutes of Health guidelines and by the
Institutional Animal Care and User Committee of Henry Ford
Health Systems and Georgia Regents University. The study
protocols was approved by the Ethics Committees of Henry
Ford Health Systems and Georgia Regents University.

Animal model
Nude rats (RNU nu/nu) (Charles River Laboratories, Inc.,
Frederick, MD, USA), ∼150–170 g in weight, were included
in this study. An orthotopic glioma model was established by
injecting human glioma U251 cells (4×105), suspended in 5 µL
of serum-free Roswell Park Memorial Institute (RPMI) 1640,
into the right hemisphere of the brain. The suspended cells
were injected at 3 mm to the right and 1 mm anterior to bregma
according to the previously published methods.16,19,28,29

Drug treatments and schedule
Establishing a tumor model that mimics clinical scenarios
has become a very important aspect in preclinical research.
Animals were randomly assigned to two treatment schedules.
The first sets of animals were designated to mimic a clinical
scenario, in which treatment was started after diagnosing
OncoTargets and Therapy 2016:9
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an established tumor in a hypoxic microenvironment and
prominent neovascularization. We waited for 7 days after
implantation, allowing the tumor to grow ~3 mm in size,
and started the treatment on day 8, 5 days/wk until day 21.
The second sets of animals were designated to mimic clinical
postsurgical cases, in which a small number of cells may
remain outside of the surgical field, resulting in a recurrent
tumor. Animals in this group were treated from day 0, along
with tumor implantation, 5 days/wk until day 21. In both
treatment schedules, the animals were further divided into
the following four treatment groups: vehicle, vatalanib alone
(50 mg/kg/d orally), HET0016 alone (10 mg/kg/d, intraperitoneally), and vatalanib plus HET0016. The doses of the
drugs were selected according to our own publications, as
well as other reports.30,31 All the animals underwent MRI on
day 22, followed by euthanasia.
Each of the postmortem subgroups were divided for either
protein array or immunohistochemistry (IHC). There were a
total of 75 animals. Out of 75, five animals were excluded due
to failure of MRI acquisition or early death of the animals.
MRI vascular parametric analysis was not possible in seven
animals due to faulty intravascular injection; however, these
animals were used for analysis of either IHC or protein
array. There were 14 animals in the vehicle (control) group
(nine animals for 8–21 days and five animals for 0–21 days),
19 animals for vatalanib treatments (eleven animals for
8–21 days and eight animals for 0–21 days), 19 animals for
HET0016 treatments (eleven animals for 8–21 days and eight
animals for 0–21 days), and 18 animals for combined vatalanib and HET0016 treatments (ten animals for 8–21 days
and eight animals for 0–21 days).

In vivo MRI
As noted earlier, all animals underwent MRI on day 22,
according to their treatment schedules. Animals were
anesthetized with 2% isoflurane and steadily supplied with
oxygen while secured to a customized cradle. All studies were
performed in a Varian (now Agilent Technologies, Santa
Clara, CA, USA), 7 T, 20 cm bore system with a DirectDrive
spectrometer and console. The maximum strength and rise
time of gradient were 250 mT/m and 120 µs, respectively.
All MRI image sets were acquired with a 32×32 mm2 field
of view. Animals were first located with the tumor center
corresponding to the magnet center by a triplanar fast low
angle shot sequence. Subsequent scans were acquired using
T1-weighted (pre- and postcontrast), T2-weighted, dual
gradient echo with a variable flip angle, and dual gradient echo DCE-MRI scans to estimate Ktrans, Kep, vp, and
ve. The pre- and postcontrast T1-weighted images were
submit your manuscript | www.dovepress.com
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acquired in a spin-echo T1-weighted multislice sequence
(repetition time [TR]/echo time [TE] =800/15.68 ms,
128×96 matrix, 27 slices [0.4 mm thick and gap 0.1 mm],
and number of summed acquisitions [NEX] =4). Spin-echo
T2-weighted images were obtained using standard twodimensional Fourier transformation multislice (27 slices,
0.4 mm thick and gap 0.1 mm) multiecho sequence: TE/
TR =20, 40, 60, 80/3,000, 128×96 matrix, and NEX =2.
Prior to the DCE-MRI sequence, and immediately after, two
Driven Equilibrium Single Pulse Observation of T1 (DESPOT1) sequences32 were run, using a dual-echo SPGRE
sequence (the “mgems” sequence in the Agilent VnmrJ
library) allowing a voxel-by-voxel estimation of T1 in the
tissue pre- and post-CA administration. DESPOT1 sequence
parameters are as follows: flip angles =3°, 5°, 7°, 12°, 15°,
25°, 45°, and 70°, matrix 128×64, seven 1.8 mm slices on
2 mm centers, and TE/TR =2.0, 4.0/80 ms. The DCE-MRI
sequence was a dual-echo SPGRE (2GE) sequence with the
same geometry and timing as the DESPOT1 sequence but
with a fixed flip angle of 35° and an acquisition of 150 image
sets at 5.13 s intervals for a total run time of ∼12.8 minutes.
At image 15 of the 2GE sequence, a bolus injection of the
CA (Magnevist; Bayer Healthcare Pharmaceuticals, Wayne,
NJ, USA), 0.25 mmol/kg at undiluted concentration, no
flush, was performed by hand push, followed by a slight
drawback.

Tumor volume analysis
Postcontrast T1-weighted images were used to determine
the tumor volume. Two investigators, blinded to the various
treatment groups, determined the volume by drawing irregular region of interests (ROIs) for all slices containing tumor.
To calculate the exact volume, investigators summed up the
number of slices and multiplied it by the slice thickness.

endothelium and blood–brain barrier into the interstitial
space, kep is the transfer rate constant from the interstitial
compartment to the vascular compartment, and vp is the
fractional volume of the CA’s vascular distribution space,
usually thought to be the plasma distribution space. The
plasma fractional volume and the blood fractional volume
are related via the following relationship: (vb = vp/[1 - Hct]),
where Hct is the average hematocrit in the vessels of the
voxel and vb is blood fraction volume.

ΔR1 calculation

Under experimental conditions, ie, using a dual-echo gradient
echo sequence (the “mgems” sequence in the Agilent VnmrJ
library), and assuming that the flip angle is known across the
brain of the rodent, an estimate of the time trace of ∆R1 can
be calculated from the following equation:
M 0 Sin(θ )(1 − e − TR * R1 ( t )) e − TE* R 2 ( t )
*

S (t ) =

1 − Cos(θ )e

1



where S(t) is the signal intensity at time t, M0 is the equilibrium
magnetization of the protons, θ is the flip angle, TR is the
repetition time between pulses, TE is the echo time (the time
between the center of the excitation pulse and the readout gradient), and R*2(t) is the transverse relaxation rate. Equation 2
can be solved for R1(t):
 

1 −  S (t )Cos(θ )  
TE
 
−

  M 0 e T 2* Sin(θ )  
1
ln 
R1 (t ) =

TR  

S (t )

1 − 
TE
−



T
2
*
Sin(θ )  
  M0e

Kinetic analysis

(3)



The model equation

Numerical methods – processing

Since the basic approach to the pharmacokinetics of DCE
studies has been previously published,27,33,34 we proceeded to
the model equation associated with the full standard model
used for parametric estimates33 as follows:

Using data from the DESPOT1 studies performed before
and after the 2GE DCE-MRI study, voxel-by-voxel maps of
T1 pre and postcontrast were generated by nonlinear least
squares fitting.27 Given the T1 maps and dynamic 2GE data
before and following the CA injection, the concentration–
time curve of the CA was approximated by the calculated
∆R1 variation in time, using Equation 3. As mentioned in
previous publications,33–35 a scaled radiological input function
was used as the arterial input function in all studies. A global
starting point was selected, usually one or two time points
after the arrival of the indicator in the vasculature, and the

t

∆R1t (t ) = K trans ∫ e − kep ( t −τ ) ∆R1p (τ )dτ + vp ∆R1p (t )  (1)
0

where R1p is the longitudinal relaxation rate of all protons in
the blood plasma, R1t is the longitudinal relaxation rate of
all protons in the tissue, Ktrans is the unidirectional volume
transfer rate of the indicator from plasma across the vascular
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next 105 data points (~9 minutes) were fitted by minimizing
the sum of squared error. A model selection paradigm was
used27,33 to ensure the stability in the parametric estimates.
In model 3 regions, the regions where the full model of
Equation 1 could be fitted, Ktrans, Kep, vp, and ve, of the whole
tumors (control and treated), were determined by drawing
irregular ROIs on ImageJ (NIH, Bethesda, MD, USA). Multiple investigators, blinded to both groups, determined the
vascular parameters from the whole tumor. For the whole
tumor, an irregular ROI was drawn.

Protein extraction from glioma

Euthanized animals were perfused with ice cold ×1
phosphate-buffered saline. Brain tissues were collected and
snap frozen immediately for preservation. For protein extraction, both hemispheres were separated, and surrounding tissue
around the tumor was carefully removed. Next, investigators
carefully cut the sections into small pieces and pulverized
the samples. The entire brain tissue processing was done on
dry ice to avoid degradation of brain proteins. The collected
tissues of the tumor were lysed using RayBiotech protocol
(RayBiotech, Norcross, GA, USA). Bovine serum albumin
provided by BioRad Protein Assay (Bio-Rad Laboratories
Inc., Hercules, CA, USA) was used as a standard to measure
total protein concentration.

Protein analysis
The following proangiogenic factors were selected and
analyzed based on positive signal intensity: angiogenin,
angiostatin, angiopoietin-1, angiopoietin-2, G-CSF, plateletderived growth factor AA (PDGF-AA), platelet-derived
growth factor receptor A (PDGF-Ra), RANTES, bFGF,
epidermal growth factor (EGF), EFGR, IGF-1, MMP-9,
SDF-1α, Tie-1, Tie-2, VEGF-A, VEGF-C, VEGFR2, and
VEGFR3. The membranes were specific for human cytokines, based on a chemiluminescent-labeling quantitative
methodology. The developed membranes were imaged using
a Multispectral Imaging System (Carestream). Later, the
acquired images were analyzed measuring the signal intensity
(pixel density) using ImageJ software. All signals emitted
from the membrane were normalized to the positive control
spots of the corresponding membrane.

Histopathology
Animals were euthanized and perfused by intracardiac
injection of 100 mL ice cold ×1 phosphate-buffered saline,
followed by 3% paraformaldehyde solution. All collected
brain specimens were fixed in a solution containing

OncoTargets and Therapy 2016:9
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3% paraformaldehyde and 3% sucrose. Tissue sections
were processed via either frozen or paraffin blocks for
standard histology staining procedures. Our focus being
on angiogenesis, proliferation, and human-specific marker
to determine the position and number of invasive cells, we
selected appropriate antibodies to target specific sites in the
glioma. Von-Willebrand factor was used as the marker (Dako
Denmark A/S, Glostrup, Denmark) for angiogenesis, Ki-67
(EMD Millipore, Billerica, MA, USA) was used to detect
the proliferation, and major histocompatibility complex
class 1 (MHC-1; now human leukocyte antigen A [HLA-A];
Abcam, [San Francisco, CA, USA]) was used for humanspecific marker.

Evaluation of microvessel density
Von-Willebrand factor IHC helped to detect the microvessel
in the tumor environment for determining angiogenesis.36–38
After tissue samples were stained, slides were microphotographed in five different areas, in which highly concentrated
tube-like formations were observed. Images were taken at ×40
magnification with the AmScope microscope. Microvessel
density (MVD) was determined by ImageJ using the colorthresholding image analysis method, in which highly dense
positively stained vessels were highlighted and measured.
A minimum of two investigators separately conducted the
analysis to determine reproducibility and alleviate a biased
estimation.

Evaluation of proliferation
Ki-67 IHC helped to detect the proliferation status of tumor
cells. Slides were stained and microphotographed in five
different areas (center, left, right, upper, and lower). In
each image taken, all cells were counted (total cells), brown
(positive for Ki-67) and blue (hematoxylin positive) cells.
The proliferation rate was calculated by dividing the total
number of brown cells (positive for Ki-67) by total number
of cell (brown and blue cells).

Evaluation of invasive tumor cells
(MHC-1)
MHC-1 IHC helped to detect cells that expressed human
markers (ie, human U251 glioma cells in rat brain) and to
determine the distance between the invasive MHC-1-positive
cells from the primary tumor mass. Images were taken at
low magnification, ×4 and ×10, to view the invasive cells
away from the periphery of the primary tumor mass. The
tumor periphery was confirmed on high magnification before
all measurements. An irregular line was drawn at the most
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peripheral part of the tumor, which showed continuation to
the primary tumor mass. Any MHC-1-positive cells away
from the drawn line were considered invasive cells. A perpendicular line was drawn from the invasive tumor cells or
tumor foci (center of the foci) to the drawn line at the tumor
periphery, and the distance was noted. Distance from the
migrated individual cell or distal tumor foci to the periphery
of the primary tumor mass was determined, and the average values were calculated. The analysis was done using
the software supplied by the vendor (ToupView Software;
ToupTek Photonics Co. Ltd, Irvine, CA, USA).16 After many
data points were collected, all distances were averaged and
represented in micrometer (µm).

Statistical analysis
Comparisons between drug- and vehicle-treated groups were
done by using a one-way analysis of variance with protected
9DWDODQLE

Results
Combination of HET0016 and vatalanib
attenuated the refractory tumor growth
observed with vatalanib alone
Significant differences in tumor volume were observed
among the treatment groups or between the two treatment
schedules (Figure 2). When the treatment started on day 8
following implantation of tumor cells, vatalanib showed
significantly (P=0.0368) increased tumor volume, as shown
by MRI on day 22 (Figure 2, upper and lower panels). The
effect of vatalanib on tumor growth is similar to that of our
previously published data.16,19 The addition of HET0016 to
vatalanib attenuated the refractory tumor growth observed
+(7
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least significant difference (PLSD) post hoc test. All results
were expressed as mean ± standard error of mean. A P-value
,0.05 was considered significant in all analysis.
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Figure 2 Tumor volume.
Notes: Representative postcontrast T1-weighted images show enhanced tumor from different groups of animals. Tumor volumes were measured by drawing appropriate
ROIs on each postcontrasted T1-weighted slice per animal. All of the slices were summed and multiplied by slice thickness. Semiquantitative analysis shows significantly
increased tumor volume in groups of animals that received vatalanib from day 8 and continued for 2 weeks. *Significant difference from vehicle-treated animals (P,0.05).
Abbreviations: ROI, region of interest; HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.
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HET0016, in combination with vatalanib,
altered the permeability transfer constant
and but not the other vascular parameters
The results from our vascular parametric analysis relayed
valuable information about the vascular kinetics in the
tumor environment (Figure 3A and B). The first parameter
we checked was the vp. There were no differences in vp
values among the groups of animals when the treatment
started on day 8 (8–21 days) (Figure 3A). The second
parameter we analyzed was the vascular forward permeability transfer constant (Ktrans), in which we noted a significant difference between vehicle- and combination of
HET0016 plus vatalanib-treated groups (P=0.0232), when

$

HET0016 treatment in developed
tumor increased the expression of
proangiogenic factors
The 20 proangiogenic factors/receptors were analyzed from
the tumor lysate to determine which factors/receptors were

. WUDQV
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3ODVPDYROXPHIUDFWLRQ

animals were treated 8–21 days (Figure 3A). The other
two parameters, backward transfer constant (K ep) and
interstitial space volume (ve), were analyzed and proved no
significant differences among the groups in both treatment
schedules. vp was significantly different among the groups
of animals that were treated early (0–21 days). There were
significant differences observed between vehicle vs vatalanib (P=0.0071) and vehicle vs HET0016 (P=0.0065),
when animals were treated from 0 to 21 days (Figure 3B).
Although the vp was lower when both drugs were used in
combination, significant differences were not achieved
between the vehicle- and the combination of HET0016 plus
vatalanib-treated groups.

±GD\VWUHDWPHQW

YS

PLQ

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 64.118.218.38 on 05-Jan-2017
For personal use only.

with vatalanib alone when the treatment started on day 8.
When the treatment started on the day of the tumor implantation, HET0016 and combined treatment showed decreased
tumor volume, although a statistically significant difference
was not achieved.
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Figure 3 Vascular parameters.
Notes: Representative images of different vascular parameters and semiquantitative analysis in groups of animals that received treatment on day 8 (A) and on day 0 (B).
Vascular parametric maps were created from dynamic contrast-enhanced magnetic resonance imaging. Vascular parametric values were measured by drawing appropriate
ROIs on representative images per animal. On the one hand, early treatment with vatalanib and HET0016 (started on day 0) caused significant decrease in tumor plasma
volume. On the other hand, late treatment (started on day 8) with the combination of HET0016 and vatalanib caused significant increase in permeability (Ktrans). *Significant
difference from vehicle-treated animals (P,0.05 to ,0.01).
Abbreviations: ROI, region of interest; HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.

modulated during the treatments. Figure 4 and Table 1
summarize the values of different factors following treatments
in two different treatment schedules, and significant differences among the groups. There were six growth factors
(G-CSF, PDGF-Ra, PDGF-AA, bFGF, EGF, and EGFR)
upregulated when animals were treated from 8 to 21 days
with HET0016 compared with that of corresponding vehicletreated animals. Along with the six growth factors, angiogenin (P=0.0173), angiostatin (P=0.0075), and RANTES
(P=0.0010) were also upregulated when compared with
vehicle. However, there were no significant differences
observed for any of the factors between vehicle vs vatalanib
and vehicle vs combined treatment groups when the treatment
started on day 8 (8–21 days).
Interestingly, the 0–21 days treatment group did not
show similar trends between vehicle vs HET0016 compared with that of the 8–21 days treatment group. Tie-1
1212
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(P=0.0264) and VEGFR3 (P=0.0401) were the only two
factors that showed upregulation in the 0–21 days treatment
group.

Treatments did not alter MVD
MVD analysis was performed to observe the neovascularization in the tumor following different treatments. There were
no significant differences in either of the treatment schedules
or among the treatment groups (Figure 5). Comparing across
both treatment schedules, we observed no change in the
density of vessels.

Combined treatments of HET0016 and
vatalanib decreased proliferation of cells
in tumors
Ki-67 staining was performed to observe the proliferation
of the tumor cells in different drug-treated animals. The bar
OncoTargets and Therapy 2016:9
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Figure 4 Protein array analysis.
Notes: Custom-designed protein array membrane was used to determine the expression of different growth factors and cytokines. The protein array membranes were
imaged using luminescence imager, and each spot with signal intensity was measured using a circular ROI. The ROI size was kept consistent from array to array and spot to
spot, making the variation subtle. Protein array values normalized to corresponding positive control show differential expressions of proangiogenic and growth factors based
on the schedules of treatments and the added drugs. Late treatment with HET0016 caused significantly increased expression of many factors.
Abbreviations: ROI, region of interest; HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; G-CSF, granulocyte colony-stimulating factor; PDGF-Ra, plateletderived growth factor receptor A; PDGF-AA, platelet-derived growth factor AA; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; SDF-1α, stromal cell-derived factor-1 alpha; VEGFR, vascular endothelial growth factor receptor.

graphs show (Figure 6) no statistically significant differences
among the groups that were treated from 8 to 21 days, but in
treatment schedule 0–21 days, combination of HET0016 plus
vatalanib-treated group shows significantly lower (P=0.015)
proliferation compared with that of other groups, including
the vehicle.

P,0.0001) (Figure 7). However, the results were different
when the treatment started on day 0 (0–21 days). Treatment
with HET0016 alone did not decrease the migration of tumor
cells, whereas treatment with vatalanib alone or vatalanib plus
HET0016 caused significantly decreased migration of tumor
cells compared with that of vehicle-treated group.

HET0016 treatment decreased migration
of tumor cells

Discussion

MHC-1 staining was performed to observe human glioma
tumor cells deep into the rat brain to determine the migration
or invasion of tumor cells. All of the drugs caused significantly
decreased migration of human cells from the primary tumor
mass to deeper part of surrounding rat brain when compared
with that of vehicle-treated animals in the 8–21 days
treatment schedule (vehicle vs vatalanib, P,0.0001;
vehicle vs HET0016, P,0.0001; and vehicle vs combined,
OncoTargets and Therapy 2016:9

The results of our studies demonstrated that the effect of
vatalanib and HET0016 on glioma is dependent on the timing
of the administration of the drug, with respect to the stages
of tumor development. We also demonstrated that HET0016,
a selective competitive inhibitor of the synthesis of 20-HETE,
in combination with vatalanib, is capable of controlling the
tumor growth, tumor cell proliferation, cell migration, and different vascular parameters (although not significantly for all).
20-HETE, a metabolite of arachidonic acid (AA) produced
submit your manuscript | www.dovepress.com
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Table 1 Effect of treatments on protein expression pattern of proangiogenic factors/receptors in glioblastoma tumor
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Proangiogenic factors

Angiogenin
Angiostatin
Angiopoietin-1
Angiopoietin-2
G-CSF
PDGF-Ra
PDGF-AA
RANTES
bFGF
EGF
EGFR
IGF-1
MMP-9
SDF-1α
Tie-1
Tie-2
VEGF-A
VEGF-C
VEGFR2
VEGFR3

Treatment 0–21 days

Vehicle vs HET0016

Vehicle vs vatalanib
(PTK787)

Vehicle vs HET0016

Vehicle vs combined

P=0.0173
P=0.0075
NS
NS
P=0.0271
P=0.0222
P=0.0025
P=0.0010
P=0.0118
P=0.0062
P=0.0005
NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
P=0.0202

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS

P=0.0264
NS
NS
NS
NS
P=0.0401

P=0.0414
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
P=0.0176

Abbreviations: HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; NS, not significant; G-CSF, granulocyte colony-stimulating factor; PDGF-Ra, platelet-derived
growth factor receptor A; PDGF-AA, platelet-derived growth factor AA; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; EGFR, epidermal growth factor
receptor; SDF-1α, stromal cell-derived factor-1 alpha; VEGFR, vascular endothelial growth factor receptor.

by the CYP4A and CYP4F enzyme families, may act as a
second messenger for the vasoactive and mitogenic responses
of some growth factors, including angiotensin II, norepinephrine, endothelin, vasopressin, serotonin, and EGF, and can be
an important mediator of VEGF, inducing angiogenesis.24,39,40
VEGFR2 tyrosine kinase inhibitor, vatalanib, increased
the tumor volume and permeability when the drug was
administered in a developed tumor (days 8–21 treatment).
The current findings are in parallel with our previously
published reports.16,19 To our surprise, permeability was significantly increased when vatalanib was added to HET0016.
The mechanisms of increasing permeability following
vatalanib treatment are not straightforward. Our previous
publications indicated paradoxical expression of hypoxiainducible factor-1α (HIF-1α) at the peripheral part of the
tumor following vatalanib treatment, which caused increased
production of SDF-1α and VEGF. In the same publications,
we indicated dilated vessels at the peripheral part of the
tumors.19 SDF-1α is also known to mobilize bone marrowderived progenitor cells, which induce neovascularization by
vasculogenesis.20,41,42 Our recent data also proved increased
mobilization and accumulation of bone marrow progenitor
cells in the tumors following vatalanib treatments.43 Any
type of neovessels (both angiogenesis and vasculogenesis)

1214

Powered by TCPDF (www.tcpdf.org)

Treatment 8–21 days

submit your manuscript | www.dovepress.com

Dovepress

would be permeable to the administered MRI contrast agent.
However, it is not clear why combined treatment (addition
of HET0016) would make blood vessels more permeable.
HET0016 is shown to normalize blood vessels in the tumor
when administered early in the tumor development31 and
also inhibit the VEGF-mediated proliferation and migration
of EPCs.26 Because of the developed tumor, HET0016 might
not have worked as expected, and the addition of vatalanib
enhanced neovascularization. However, when both vatalanib
and HET0016 were administered together on the day of tumor
implantation (0–21 days treatment), tumor volume, tumor
blood volume, permeability, and extravascular and extracellular space volume were decreased when compared with the
corresponding vehicle-treated group. The results indicate the
importance of early treatment as soon as the tumor is resected
without being delayed for the appearance of recurrent tumor.
It should be mentioned that our postsurgical mimic may not
reflect the exact clinical scenario, where leftover cells are
already embedded in the surrounding microenvironment with
established circulation. However, based on our findings, early
treatment would decrease tumor invasion.
There has been no report showing the effects of HET0016
on the expression level of different growth and proangiogenic
factors in GBM. Investigators have shown increased level of
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Figure 5 Mean vascular density.
Notes: Five different, highly dense vascular areas were photomicrographed within the tumor mass. Each image was thresholded in ImageJ, making sure only the vWF-positive
staining was highlighted and positive areas were noted. Analysis of mean vascular density and histochemical images show no significant increased or decreased vascular density
for following early or late treatments. IHC images were taken at ×40 magnification.
Abbreviations: vWF, Von-Willebrand factor; IHC, immunohistochemistry; HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.

VEGF and MMP-9 in tumors that overexpress cytochrome
P450 ω-hydroxylase, which converts AA to 20-HETE that
induces angiogenic responses in vivo and in vitro,44,45 and
HET0016 inhibits the synthesis of 20-HETE. HET0016 is
shown to inhibit the angiogenic response to EGF, VEGF, and
bFGF.24,46 Given the complexity of the angiogenic process,
we evaluated several proangiogenic factors to determine their
behaviors during the treatment. Current consensus is that
VEGF is the most important proangiogenic factor, and it can
be modulated and stimulated by several other growth factors.
VEGF expression by tumors is upregulated by hypoxia and
is often elevated near the areas of tumor necrosis or at the
periphery.19 Hypoxia activates an HIF-1α-binding sequence
in the VEGF promoter, which leads to VEGF messenger
RNA transcription and stability. Guo et al47 showed that
20-HETE first caused an increase in VEGF, which in turn
causes the upregulation of HIF-1α. The resulting activation of

OncoTargets and Therapy 2016:9

HIF-1α in these cancers leads to the transcriptional induction,
not only of VEGF and VEGFRs but also of endothelin-1,
angiopoietins, and angiopoietin receptors (Tie-1 and -2).
HET0016 treatment (8–21 days schedule) increased the
expression of PDGF-Ra, PDGF-AA, bFGF, EGF, and EGFR,
which are well-known proangiogenic factors. In our previous
study on a breast cancer model, we noticed two different
phenomena.48 With a short-term treatment with HET0016,
all these aforementioned factors were downregulated, which
was also seen in our in vitro studies (data not shown). The
findings are also supported by Guo et al, who had shown
that short-term treatment with HET0016 inhibited EGFR in
U251 cells.46 However, when the treatment was continued
for a longer period of time, there was an upregulation of
these factors in the breast cancer.48 In the current studies,
we also noticed two phenomena. When the treatment was
started on day 8, these factors were upregulated, whereas
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Figure 6 Proliferative capacity.
Notes: Histochemical images and analysis of proliferative capacity of the tumor cells following different treatments. Five different regions with higher expression of ki67
were taken within the tumor mass, and brown and blue cells were counted in total. The total number of browns cells (Ki-67 stained) was divided by the total number of
cells (blue and brown cells). Combined HET0016 and vatalanib treatment started on day 0 caused significantly lower proliferative cells in the tumor. IHC images were taken
at ×40 magnification. *Significant difference from vehicle-treated animals (P,0.05).
Abbreviations: HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; IHC, immunohistochemistry; Vata, vatalanib.

when the treatment started on day 0 (on the day of tumor
implantation), we did not notice any upregulation of these
factors. We believe that the changes are due to different
tumor cells (breast cancer vs glioma), treatment schedules,
and activation of compensatory downstream EGFR signaling
mechanisms for survival of tumor. Similar expressions were
not observed when HET0016 was combined with vatalanib.
Although these factors were increased, there was no increase
in angiogenic response in treated tumors as indicated by
nonsignificant changes in MVD in all treatment groups.
The observed paradoxical effects indicate the importance
of timing of treatment in tumors using HET0016 alone or in
combination of vatalanib. Chronic inhibition of 20-HETE
signaling decreased EGFR phosphorylation in mouse cystic
kidneys, suggesting that 20-HETE has the ability of coupling
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and transactivation of EGFR.49 Similar effects were also
found in U251 glioma cells, where 20-HETE inhibition
by HET0016 reduced an EGFR activation, and subsequent
proliferation stimulated by EGF.46,47 These findings are
in accordance with our results when treatment started on
day 0. On the other hand, preceding studies have indicated
exacerbated signaling of multiple members of the EGFR
family, often causing uncontrolled proliferation of cancer
cells, possibly justifying the reason for high levels of EGF
and EGFR in tumors when the treatment started on day 8 (in
a developed tumor) in our study.50
Unlike previous studies, our results did not indicate
decreased proliferation capacity of the tumor cells in either
of the treatment schedules or in any of the treatment groups
except the combined early treatment (day 0). We believe, due
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Figure 7 Invasion of tumor cells.
Notes: Migration of cell was determined by drawing a perpendicular line from the migrated cells to the periphery of the primary tumor mass. When the distances the
tumor cells migrated away from the central tumor mass were determined, there were significantly decreased invasion following late treatments with vatalanib, HET0016, and
combination of HET0016 plus vatalanib. Both vatalanib and combined treatments started on day 0 (early treatment) caused significantly decreased invasion of tumor cells. The
following symbols show the comparison among different groups. *Significant difference from vehicle-treated animals (P,0.0001). #Significant difference between vatalanib vs
HET0016 alone or combined treatments (P,0.0001). @Significant difference between HET0016 vs vatalanib or combined treatments (P,0.0001).
Abbreviations: HET0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.

to low plasma availability and single-dose administration, it
yielded no changes, when compared with previous studies, in
which two injections per day were administered. When comparing the invasion of the tumor cells following treatments,
all animals in late treatment groups (days 8–21) showed
significant decrease in cell migration/invasion in comparison
to corresponding vehicle-treated animals. On the other hand,
decreased cell migration in vatalanib- and combined-treated
animals was observed only in the early treatment groups.
These differential effects can be explained as follows:
1) day 8 treatment has already developed tumor with an established microenvironment and 2) day 0 treatment has no established microenvironment, except tumor cell. The decrease
in migration suggests that the treatment somehow decreased
the invasiveness by affecting the microenvironment (stromal
cells) at the invasive front (periphery of tumor), indicating
that inhibitors have more effect on the microenvironment

OncoTargets and Therapy 2016:9

rather than the tumor cells. Different chemokine/growth factors and receptors are implicated for tumor cells to become
migratory or invasive phenotypes.51,52 One of the complexes
is SDF-1/CXCR4, which increases the binding of tumor cells
to extracellular matrix through α5β3 integrin activation.52,53
Recently, investigators have demonstrated that α5β1 integrin
binds to activate c-Met, which initiates Src/FAK signaling
and promotes migration in ovarian cancer cells.54 Integrin
EGFR macromolecular signaling complexes are also implicated for the changes in phenotype from normal epithelial
to migratory cell types in breast cancer.55,56 Other growth
factors, such as EGF and IGF-1 have also been shown to
increase migratory capacity of different malignant cells.51
Wild-Bode et al have demonstrated that activity of MMP-2
and MMP-9 is the best predictor of glioma cell migration
in an in vitro study.57 Other investigators have also pointed
out the importance of MMPs in cell migration and invasion
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in glioma.58 We also reported increased migration of glioma
cells following sublethal irradiation, which caused increased
expression of CD44 and MMP-2.59 Despite increased EGF
and EGFR expression (protein array data) with HET0016,
there was no increased cell invasion/migration away from the
primary tumor mass, which could be due to the attenuation of
MMP-9. In both early and late HET0016 treatment groups,
MMP-9 was lower (borderline significant differences) compared with vehicle-treated animals.

Conclusion
In summary, our results demonstrated that HET0016, a
selective competitive inhibitor of the synthesis of 20-HETE,
alone or in combination of VEGFR2 tyrosine kinase inhibitor
(vatalanib), is capable of attenuating the tumor growth,
tumor cell proliferation, cell migration, and different vascular parameters. However, all of these observations are contingent upon respective tumor developmental stages, timing,
and selection of the appropriate drug administered.
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